芳香化酶抑制剂联合生长激素治疗青春期身材矮小症男性患儿的临床研究

doi:10.3785/j.issn.1008-9292.2020.04.06

浙江大学学报（医学版）

2020, Vol. 49

Issue (3): 283-290 DOI: 10.3785/j.issn.1008-9292.2020.04.06

专题报道：芳香化酶抑制剂的临床应用

芳香化酶抑制剂联合生长激素治疗青春期身材矮小症男性患儿的临床研究

孔元梅(

),陈虹,梁黎,郑卯昵,方燕兰,王春林*(

)

浙江大学医学院附属第一医院儿科, 浙江杭州 310003

Aromatase inhibitors combined with growth hormone in treatment of adolescent boys with short stature

KONG Yuanmei(

),CHEN Hong,LIANG Li,ZHENG Maoni,FANG Yanlan,WANG Chunlin*(

)

Department of Pediatrics, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China

全文: PDF(1058 KB)

HTML( 28 )

摘要：

目的: 研究第三代非甾体类芳香化酶抑制剂（AI）改善大骨龄（≥13岁）男性身材矮小症青少年成年身高的有效性，同时监测药物的安全性。方法: 2015年12月—2018年11月在浙江大学医学院附属第一医院就诊的预测成年身高受损的骨龄为13~15岁的青春期男性患儿151例，经充分告知AI的潜在风险后，由患儿及其家长选择入组：重组人生长激素（rhGH）联用AI组108例（联用AI组），单用rhGH组43例（rhGH单用组）。治疗时间12月以上，每3个月复查一次，监测药物不良反应。结果: 与rhGH单用组比较，联用AI组骨龄差值与时序年龄差值的比值（ΔBA/ΔCA）、骨龄别身高标准差分值的差值（ΔHtSDS_BA）以及预测成年身高的差值（ΔPAH）改善更加明显（P < 0.05或P < 0.01）。随访期间，联用AI组尿酸升高69例（63.9%），高密度脂蛋白（HDL）降低56例（51.9%），严重痤疮、兴奋多动、性格暴躁28例（25.9%），膝关节疼痛12例（11.1%），骨折5例（4.6%），轻度肾功能异常3例（2.8%），精神不振、嗜睡、记忆力减退和成绩下降2例（1.9%），轻度肝功能异常2例（1.9%），空腹血糖受损1例（0.9%），粒细胞减少1例（0.9%），停药后监测指标逐渐恢复正常。rhGH单用组出现膝关节疼痛5例（11.6%），空腹血糖受损1例（2.3%）。结论: 长疗程的AI联合rhGH治疗可以延缓骨龄增长，有效改善青春期大骨龄矮小男性患儿的成年终身高，但治疗期间需要密切监测AI的不良反应。

关键词： 身材矮小症; 芳香酶抑制剂; 重组人生长激素; 青春期; 男童; 治疗效果; 安全性; 身材矮小症; 芳香酶抑制剂; 重组人生长激素; 青春期; 男童; 治疗效果; 安全性

Abstract:

Objective: To assess the efficacy and safety of aromatase inhibitors (AIs) combined growth hormone in treatment of adolescent boys with short stature. Methods: One hundred and fifty-one short stature pubertal boys with age of 10-14 years and bone age of 13-15 years, who were admitted to the Department of Pediatrics, the First Affiliated Hospital, Zhejiang University School of Medicine, were included in this trial. According to their own or parents' intention, the children were divided into recombinant human growth hormone (rhGH)+AI group (n=108) and rhGH group (n=43). All children were injected subcutaneously with rhGH 0.15-0.2 IU·kg^-1·d^-1, and those in rhGH+AI group were additionally given 2.5 mg/d letrozole or 1 mg/d anastrozole, orally for 12 months or longer. The children were followed-up every 3 months. During the follow-up visit, the predicted adult height (PAH), sex hormone level, glucose and lipid metabolism, and other indicators were measured, and adverse reactions were monitored. Results: After intervention, there were significant differences in ΔBA(bone age)/ΔCA(chronological age), ΔHtSDS_BA(height standard deviation score based on bone age)and ΔPAH between rhGH+AI group and the rhGH group(P < 0.05 or P < 0.01). During follow-up, 63.9%of the children in the rhGH+AI group had elevated uric acid and 51.9%had decreased high-density lipoprotein (HDL); 25.9%showed severe acne, excitement, hyperactivity and irritability, 11.1%had knee pain; 4.6%had fracture; 2.8%had mild renal dysfunction; 1.9%had inactivity, drowsiness, memory loss and performance decline; 1.9%showed mild abnormal liver function; 0.9%showed impaired fasting glucose; 0.9%showed granulocytopenia. In the rhGH group, 11.6%of the children presented with knee pain and 2.3%with impaired fasting glucose. Conclusions: AI combined with rhGH can delay the growth of BA and effectively improve the PAH of adolescent boys with larger bone age. However, the occurrence of adverse reactions of AI should be closely monitored during treatment.

Key words: Short stature Aromatase inhibitors Recombinant human growth hormone Puberty Boys Treatment outcome Safety Short stature Aromatase inhibitors Recombinant human growth hormone Puberty Boys Treatment outcome Safety

收稿日期: 2020-01-09 出版日期: 2020-05-29

CLC:

R588

基金资助: 浙江省科技计划(2020C03121);浙江省教育厅科研项目(Y201840363);浙江省科技计划(2020C03121);浙江省教育厅科研项目(Y201840363)

通讯作者: 王春林 E-mail: 6512039@zju.edu.cn;hzwangcl@zju.edu.cn

作者简介: 孔元梅(1987-), 女, 硕士, 主治医师, 主要从事生长性疾病研究; E-mail:6512039@zju.edu.cn; https://orcid.org/0000-0002-3250-1892|孔元梅(1987-), 女, 硕士, 主治医师, 主要从事生长性疾病研究; E-mail:6512039@zju.edu.cn; https://orcid.org/0000-0002-3250-1892

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	孔元梅
	陈虹
	梁黎
	郑卯昵
	方燕兰
	王春林

引用本文:

孔元梅,陈虹,梁黎,郑卯昵,方燕兰,王春林. 芳香化酶抑制剂联合生长激素治疗青春期身材矮小症男性患儿的临床研究[J]. 浙江大学学报（医学版）, 2020, 49(3): 283-290.

KONG Yuanmei,CHEN Hong,LIANG Li,ZHENG Maoni,FANG Yanlan,WANG Chunlin. Aromatase inhibitors combined with growth hormone in treatment of adolescent boys with short stature. J Zhejiang Univ (Med Sci), 2020, 49(3): 283-290.

链接本文:

http://www.zjujournals.com/med/CN/10.3785/j.issn.1008-9292.2020.04.06 或 http://www.zjujournals.com/med/CN/Y2020/V49/I3/283

表 1 联用AI组与rhGH单用组基线资料比较

表 2 是否联用AI治疗青春期身材矮小症男性患儿疗效比较

表 3 是否联用AI治疗青春期身材矮小症男性患儿不良反应比较

1	NAVARRO R , DUNN J D , LEE P A et al. Translating clinical guidelines into practice:the effective and appropriate use of human growth hormone[J]. Am J Manag Care, 2013, 19 (15 Suppl): s281- s289
2	WIT J M , RANKE M B , ALBERTSSON-WIKLAND K et al. Personalized approach to growth hormone treatment:clinical use of growth prediction models[J]. Horm Res Paediatr, 2013, 79 (5): 257- 270 doi: 10.1159/000351025
3	HERO M , TOIVIAINEN-SALO S , WICKMAN S et al. Vertebral morphology in aromatase inhibitor-treated males with idiopathic short stature or constitutional delay of puberty[J]. J Bone Miner Res, 2010, 25 (7): 1536- 1543 doi: 10.1002/jbmr.56
4	MAURAS N , GONZALEZ DE PIJEM L , HSIANG H Y et al. Anastrozole increases predicted adult height of short adolescent males treated with growth hormone:a randomized, placebo-controlled, multicenter trial for one to three years[J]. J Clin Endocrinol Metab, 2008, 93 (3): 823- 831 doi: 10.1210/jc.2007-1559
5	PEDROSA L F , DE OLIVEIRA J M , THOMé P et al. Height increment and laboratory profile of boys treated with aromatase inhibitors with or without growth hormone[J]. Horm Metab Res, 2017, 49 (10): 778- 785 doi: 10.1055/s-0043-116944
6	MAURAS N , ROSS J L , GAGLIARDI P et al. Randomized trial of aromatase inhibitors, growth hormone, or combination in pubertal boys with idiopathic, short stature[J]. J Clin Endocrinol Metab, 2016, 101 (12): 4984- 4993 doi: 10.1210/jc.2016-2891
7	中华医学会儿科学分会内分泌遗传代谢学组 . 矮身材儿童诊治指南[J]. 中华儿科杂志, 2008, 46 (6): 428- 430 Endocrine Genetic Metabolism Group, Chinese Pediatric Society, Chinese Medical Association . Guidelines for diagnosis and treatment of children with short stature[J]. Chinese Journal of Pediatrics, 2008, 46 (6): 428- 430
8	王卫平, 孙锟, 常立文 . 儿科学[M]. 9版北京: 人民卫生出版社, 2018: 66 WANG Weiping , SUN Kun , CHANG Liwen . Pediatrics[M]. 9th Ed Beijing: People's Medical Publishing House, 2018: 66
9	HERO M , NORJAVAARA E , DUNKEL L . Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature:a randomized controlled trial[J]. J Clin Endocrinol Metab, 2005, 90 (12): 6396- 6402 doi: 10.1210/jc.2005-1392
10	ROTHENBUHLER A , LINGLART A , BOUGNèRES P . A randomized pilot trial of growth hormone with anastrozole versus growth hormone alone, starting at the very end of puberty in adolescents with idiopathic short stature[J]. Int J Pediatr Endocrinol, 2015, 2015 (1): 4 doi: 10.1186/1687-9856-2015-4
11	李辉, 季成叶, 宗心南 et al. 中国0~18岁儿童、青少年身高、体重的标准化生长曲线[J]. 中华儿科杂志, 2009, 47 (7): 487- 492 H ui , JI Chengye , ZONG Xinnan et al. Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years[J]. Chinese Journal of Pediatrics, 2009, 47 (7): 487- 492 doi: 10.3760/cma.j.issn.0578-1310.2009.07.003.LI
12	WICKMAN S , SAUKKONEN T , DUNKEL L . The role of sex steroids in the regulation of insulin sensitivity and serum lipid concentrations during male puberty:a prospective study with a P450-aromatase inhibitor[J]. Eur J Endocrinol, 2002, 146 (3): 339- 346 doi: 10.1530/eje.0.1460339
13	HERO M , ANKARBERG-LINDGREN C , TASKINEN M R et al. Blockade of oestrogen biosynthesis in peripubertal boys:effects on lipid metabolism, insulin sensitivity, and body composition[J]. Eur J Endocrinol, 2006, 155 (3): 453- 460 doi: 10.1530/eje.1.02226
14	HERO M , WICKMAN S , HANHIJ?RVI R et al. Pubertal upregulation of erythropoiesis in boys is determined primarily by androgen[J]. J Pediatr, 2005, 146 (2): 245- 252 doi: 10.1016/j.jpeds.2004.09.002
15	HERO M , MAURY S , LUOTONIEMI E et al. Cognitive effects of aromatase inhibitor therapy in peripubertal boys[J]. Eur J Endocrinol, 2010, 163 (1): 149- 155 doi: 10.1530/EJE-10-0040
16	WIT J M , HERO M , NUNEZ S B . Aromatase inhibitors in pediatrics[J]. Nat Rev Endocrinol, 2011, 8 (3): 135- 147 doi: 10.1038/nrendo.2011.161
17	SHULMAN D I, FRANCIS G L, PALMERT M R, et al. Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development[J/OL]. Pediatrics, 2008, 121(4): e975-e983. DOI: 10.1542/peds.2007-2081.
18	T'SJOEN G G , GIAGULLI V A , DELVA H et al. Comparative assessment in young and elderly men of the gonadotropin response to aromatase inhibition[J]. J Clin Endocrinol Metab, 2005, 90 (10): 5717- 5722 doi: 10.1210/jc.2005-0982
19	SHAMS K , CAMEO T , FENNOY I et al. Outcome analysis of aromatase inhibitor therapy to increase adult height in males with predicted short adult stature and/or rapid pubertal progress:a retrospective chart review[J]. J Pediatr Endocrinol Metab, 2014, 27 (7-8): 725- 730 doi: 10.1515/jpem-2013-0470
20	GOUDRIAAN A E , LAPAUW B , RUIGE J et al. The influence of high-normal testosterone levels on risk-taking in healthy males in a 1-week letrozole administration study[J]. Psychoneuro-endocrinology, 2010, 35 (9): 1416- 1421 doi: 10.1016/j.psyneuen.2010.04.005
21	KIL K E , BIEGON A , DING Y S et al. Synthesis and PET studies of[(11)C-cyano]letrozole (Femara), an aromatase inhibitor drug[J]. Nucl Med Biol, 2009, 36 (2): 215- 223 doi: 10.1016/j.nucmedbio.2008.11.010
22	SALEHPOUR S , ALIPOUR P , RAZZAGHY-AZAR M et al. A double-blind, placebo-controlled comparison of letrozole to oxandrolone effects upon growth and puberty of children with constitutional delay of puberty and idiopathic short stature[J]. Horm Res Paediatr, 2010, 74 (6): 428- 435 doi: 10.1159/000315482
23	MORRISON J A , SPRECHER D L , BIRO F M et al. Serum testosterone associates with lower high-density lipoprotein cholesterol in black and white males, 10 to 15 years of age, through lowered apolipoprotein AI and AII concentrations[J]. Metabolism, 2002, 51 (4): 432- 437 doi: 10.1053/meta.2002.31321
24	TAKIUE Y , HOSOYAMADA M , KIMURA M et al. The effect of female hormones upon urate transport systems in the mouse kidney[J]. Nucleos Nucleot Nucl, 2011, 30 (2): 113- 119 doi: 10.1080/15257770.2010.551645
25	ZENG M , CHEN B , QING Y et al. Estrogen receptor beta signaling induces autophagy and downregulates Glut9 expression[J]. Nucleos Nucleot Nucl, 2014, 33 455- 465 doi: 10.1080/15257770.2014.885045
26	BUDHIRAJA R , KAYYALI U S , KARAMSETTY M et al. Estrogen modulates xanthine dehydrogenase/xanthine oxidase activity by a receptor-independent mechanism[J]. Antioxid Redox Signal, 2003, 5 (6): 705- 711 doi: 10.1089/152308603770380007
27	BRYZGALOVA G , GAO H , AHREN B et al. Evidence that oestrogen receptor-alpha plays an important role in the regulation of glucose homeostasis in mice:insulin sensitivity in the liver[J]. Diabetologia, 2006, 49 (3): 588- 597 doi: 10.1007/s00125-005-0105-3
28	KANBAY M , SEGAL M , AFSAR B et al. The role of uric acid in the pathogenesis of human cardiovascular disease[J]. Heart, 2013, 99 (11): 759- 766 doi: 10.1136/heartjnl-2012-302535

[1]	王春林,梁黎. 第三代非甾体类芳香化酶抑制剂在儿科内分泌临床应用的再认识[J]. 浙江大学学报（医学版）, 2020, 49(3): 275-282.
[2]	于冰青,聂敏,伍学焱,茅江峰,王曦,马婉璐,季文,黄奇彬,张睿. 来曲唑有效提高性发育异常男性患儿的睾酮水平[J]. 浙江大学学报（医学版）, 2020, 49(3): 297-301.
[3]	徐德,陆文丽,王雪晴,王俊祺,谢轶雯,董治亚,王伟. 来曲唑治疗纤维性骨营养不良综合征女性患儿外周性性早熟疗效观察[J]. 浙江大学学报（医学版）, 2020, 49(3): 291-296.
[4]	王倩,张书乐,马雪,李桂梅,王增敏,王凤雪. 来曲唑对21-羟化酶缺乏型先天性肾上腺皮质增生症患儿生长发育的影响[J]. 浙江大学学报（医学版）, 2020, 49(3): 302-307.
[5]	李燕虹,杜敏联,马华梅,陈秋莉,陈红珊,张军. 来曲唑改善青春期特发性身材矮小症男性患儿成年身高的疗效评价[J]. 浙江大学学报（医学版）, 2020, 49(3): 308-314.
[6]	陈军,刘丹萍,刘莉,刘萍,徐庆年,夏露,凌云,黄丹,宋树丽,张丹丹,钱志平,李涛,沈银忠,卢洪洲. 硫酸羟氯喹治疗2019冠状病毒病(COVID-19)普通型患者的初步研究[J]. 浙江大学学报（医学版）, 2020, 49(2): 215-219.
[7]	冯梦宇,张太平,赵玉沛. 加速康复外科在胰腺外科中的应用[J]. 浙江大学学报（医学版）, 2017, 46(6): 666-674.
[8]	邹丽霞等. 人源化白细胞介素-6受体抗体治疗全身型幼年特发性关节炎的疗效及安全性[J]. 浙江大学学报（医学版）, 2017, 46(4): 421-426.
[9]	柴延兰，王娟，刘孜. 代谢组学——肿瘤个体化治疗研究的有力工具[J]. 浙江大学学报（医学版）, 2013, 42(6): 705-710.
[10]	朱铭强，傅君芬，梁黎，巩纯秀，熊丰，刘戈力，罗飞宏，陈少科. 中国儿童青少年性发育现状研究[J]. 浙江大学学报（医学版）, 2013, 42(4): 396-.
[11]	于忠, 项美香, 马长生, 张树龙, 杨延宗. 国产依布利特转复心房颤动/心房扑动的疗效及安全性研究[J]. 浙江大学学报（医学版）, 2013, 42(2): 212-216.
[12]	朱红;陈黎勤;蒋优君;梁黎. 性早熟女童血浆ghrelin水平与腺垂体激素的关系[J]. 浙江大学学报（医学版）, 2008, 37(5): 506-510.
[13]	郑斐;朱红;蒋优君;梁黎. 特发性中枢性性早熟女童GnRHa治疗前后心理行为的变化[J]. 浙江大学学报（医学版）, 2008, 37(3): 289-294.
[14]	朱红;蒋优君;梁黎;赵正言. 长效促性腺激素类似物治疗女童特发性中枢性性早熟的疗效[J]. 浙江大学学报（医学版）, 2008, 37(3): 295-299.
[15]	漆君;刘建仁;晁明;丁美萍;黄鉴政;武建军;张广强;孙继红;宋水江;张宝荣;陈伟;李慎茂. 高危颈动脉狭窄的球囊扩张和支架植入术治疗[J]. 浙江大学学报（医学版）, 2007, 36(4): 401-405.

Viewed

Full text

Abstract

Cited

Shared

Discussed